Search Clinical Trials in the European Union

Duration
16-20 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
101-112 of 112 trials

Autoimmune Disease: CAR-Expressing NK Cell Therapy

We are testing a new therapy using engineered immune cells for people with active B-cell driven autoimmune diseases. The study aims to assess safety and effectiveness in conditions like lupus and scleroderma.

Systemic Lupus ErythematosusSystemic SclerosisIdiopathic Inflammatory MyopathySafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Rezafungin for Fungal Infections in Critically Ill Patients

We are studying how Rezafungin levels change in patients on ECMO, a life-support treatment. This research aims to understand its effectiveness and any potential side effects.

Invasive Candidiasis>2 yearsConfirmation phase (III)Monitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal MedicinePulmonology

Non-Small Cell Lung Cancer: QL2107 vs. Keytruda®

We are comparing a new treatment, QL2107, to Keytruda® for patients with resected non-small cell lung cancer. The study aims to see if QL2107 works similarly in the body and to evaluate its safety and immune response.

Non-small Cell Lung Cancer1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

CEB-01 for Pediatric Abdominal Tumors

We are testing a new treatment for children with certain types of abdominal tumors to see if it is safe and effective alongside standard care. This study focuses on children from birth to under 18 years old.

Desmoplastic Small Round Cell TumorFibrolamellar Hepatocellular CarcinomaExtracranial Malignant Rhabdoid Tumor6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOncologyPediatrics

Stem Cell Transplant: New T Cell Therapy

We are studying a new treatment using special T cells to help prevent complications in patients receiving stem cell transplants from siblings. The goal is to see if this approach can safely reduce the need for other medications.

Healthy Participants6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal Medicine

Ulcerative Colitis: Mirikizumab with Tirzepatide

We are studying whether combining mirikizumab with tirzepatide helps adults with moderately to severely active ulcerative colitis and obesity achieve better remission and weight loss than mirikizumab alone.

Obesity or OverweightUlcerative Colitis1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesPartially RemoteEndocrinologyGastroenterology

Crohn’s Disease: Mirikizumab with Tirzepatide

We are studying whether a combination of mirikizumab and tirzepatide helps adults with moderately to severely active Crohn’s disease achieve better remission and weight loss than mirikizumab alone.

Crohn’s DiseaseObesity or Overweight1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

Cholangiocarcinoma: Ivosidenib Maintenance Therapy

We are studying whether the drug ivosidenib can help patients with mIDH1 cholangiocarcinoma after standard chemotherapy. The trial will also look at its safety and effects on quality of life.

Cholangiocarcinoma Treatment>2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Bipolar-I Disorder: Long-term Safety of KarXT

We are studying the long-term safety and tolerability of KarXT for people experiencing manic episodes in Bipolar-I Disorder. This trial aims to ensure that the treatment is safe for those affected.

Mania and Bipolar DisorderConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPsychiatry

Head and Neck Cancer: NBTXR3 Treatment Study

We are studying a new treatment involving NBTXR3 with or without cetuximab for elderly patients with locally advanced head and neck cancer. The goal is to see if this approach improves survival compared to standard radiotherapy.

Head and Neck Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ulcerative Colitis: SAR441566 Study

We are investigating the effects of SAR441566 in adults with moderate-to-severe ulcerative colitis. The study aims to see if different doses can help achieve remission and improve overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Mantle Cell Lymphoma: Acalabrutinib with R-CHOP

We are studying the combination of acalabrutinib and R-CHOP for patients with previously untreated mantle cell lymphoma. The goal is to see if this combination improves treatment response and is safe.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology